SuperworthAtrium Therapeutics free cash flow RNA
Cash from operations less capital spending, by quarter and over the last twelve months, from 2025.
- Last 12 months, to Jun 30, 2026
- n/m
- a quarter missing
- Latest quarter, Q2 FY26
- −$4M
Atrium Therapeutics' twelve-month free cash flow can't be added up yet: a quarter of its results is missing from our data.
In its latest quarter, Q2 FY26, it was −$4M.
Free cash flow over time
Quarter by quarter
| Quarter | Ended | Free cash flow | On a year earlier |
|---|---|---|---|
| Q2 FY26 | −$4M | n/a | |
| Q1 FY26 | −$33.2M | n/a | |
| Q2 FY25 | −$12.2M | n/a | |
| Q1 FY25 | −$11.1M | n/a |
Against its peers
Companies in Drug Manufacturers - General nearest Atrium Therapeutics' size, closest first, today.
| Company | Free cash flow yield |
|---|---|
| RNAAtrium Therapeutics | n/m |
| NATRNatures Sunshine Products | 8.5% |
| LFVNLifevantage | 9.1% |
| SPROSpero Therapeutics | n/m |
| ATNMActinium Pharmaceuticals | n/m |
| ARVNArvinas | −43.7% |
| PBYIPuma Biotechnology | 7.2% |
| IRWDIronwood Pharmaceuticals | n/m |
| ZVRAZevra Therapeutics | 5.6% |
| CRMDCorMedix | n/m |
| COLLCollegium Pharmaceutical | n/m |
| Peer median | 7.2% |
What the free cash flow tells you
Cash from operations minus capital spending. The cash the company could hand back or reinvest.
Seasonal and lumpy quarter to quarter. The TTM view is the one to trust.
More on Atrium Therapeutics
Valuation data, not investment advice. Prices as of . Reported figures come from the company's filings with the SEC.